Compare MFA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | COLL |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.0M | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | MFA | COLL |
|---|---|---|
| Price | $9.60 | $49.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $10.96 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.1M | 515.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.86 | ★ 1.63 |
| Revenue | $279,011,000.00 | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | $14.85 | $3.67 |
| P/E Ratio | ★ $11.17 | $29.92 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $7.85 | $23.23 |
| 52 Week High | $11.08 | $49.16 |
| Indicator | MFA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 71.79 |
| Support Level | $9.45 | $47.86 |
| Resistance Level | $9.72 | $49.16 |
| Average True Range (ATR) | 0.15 | 1.33 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 83.64 | 92.01 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.